Drug Profile
LOP 628
Alternative Names: Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate - Novartis; Anti-c-kit humanised IgG1/κ antibody-maytansine conjugate - Novartis; Anti-proto-oncogene protein c-kit IgG1/kappa antibody-maitansine conjugate - Novartis; Anti-proto-oncogene protein c-kit IgG1/kappa antibody-maytansine conjugate - NovartisLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals Corporation
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 01 Mar 2015 Novartis suspends phase I trial in Solid tumours and Acute myeloid leukaemia in the USA, Australia and Netherlands (NCT02221505)
- 01 Dec 2014 Phase-I clinical trials in Acute myeloid leukaemia in USA, Australia and the Netherlands (IV)